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Abstract
Background: Cardiovascular adverse events (CVAEs) associated with BRAF inhibi-
tors alone versus combination BRAF/MEK inhibitors are not fully understood.
Methods: This study included all adult patients who received BRAF inhibitors (ve-
murafenib, dabrafenib, encorafenib) or combinations BRAF/MEK inhibitors (vemu-
rafenib/cobimetinib; dabrafenib/trametinib; encorafenib/binimetinib). We utilized the 
cross- sectional FDA’s Adverse Events Reporting System (FAERS) and longitudi-
nal Truven Health Analytics/IBM MarketScan database from 2011 to 2018. Various 
CVAEs, including arterial hypertension, heart failure (HF), and venous thromboem-
bolism (VTE), were studied using adjusted regression techniques.
Results: In FAERS, 7752 AEs were reported (40% BRAF and 60% BRAF/MEK). 
Median age was 60 (IQR 49– 69) years with 45% females and 97% with melanoma. 
Among these, 567 (7.4%) were cardiovascular adverse events (mortality rate 19%). 
Compared with monotherapy, combination therapy was associated with increased 
risk for HF (reporting odds ratio [ROR] = 1.62 (CI = 1.14– 2.30); p = 0.007), arterial 
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1 |  INTRODUCTION
Targeted anti- cancer agents have significantly impacted the 
cancer treatment landscape. Recent advances in melanoma, 
colon, and lung cancer have prompted the development of a 
new class of targeted therapeutics: BRAF inhibitors.1 Based 
on positive clinical studies, vemurafenib was the first BRAF 
inhibitor to be approved by the Food and Drug Administration 
(FDA) as single- agent therapy for metastatic melanoma. 
Further research has shown that patients with metastatic 
disease may become resistant to single- agent therapy, and 
BRAF agents may not be as effective alone.2 Thus, a new 
class of drugs that target MEK downstream from the BRAF 
in the signaling cascade was recommended as a novel strat-
egy to overcome resistance and add to efficacy when used 
combined with BRAF inhibitors. Multiple combinations of 
BRAF/MEK inhibitors have recently found to be highly effi-
cacious for the use in metastatic melanoma, metastatic non- 
small cell lung cancer, and metastatic colon cancer,3– 9 which 
include vemurafenib (BRAF)/cobimetinib (MEK), dab-
rafenib (BRAF)/trametinib (MEK), and encorafenib (BRAF)/
binimetinib (MEK).
Several studies have reported drug- related cardiovascular 
adverse events (CVAE) with BRAF monotherapy; however, 
the incidence of CVAEs may be higher when used in com-
bination with MEK inhibitors.10 The most common CVAEs 
are asymptomatic reductions in left ventricular ejection frac-
tion (LVEF), symptomatic heart failure (HF), hypertension, 
QT interval prolongation, and atrial arrhythmias.11 The in-
cidence of LVEF reduction and hypertension was noted to 
be around 5%– 11% and 10%– 15%, respectively.7,9 In a re-
cent meta- analysis, it was noted that the BRAF/MEK com-
bination was associated with an increased risk of pulmonary 
embolism (relative risk [RR]  =  4.36, confidence interval 
[CI] = 1.23– 15.45), decreased LVEF (RR 3.72 [CI = 1.74– 
7.95]) and hypertension (RR 1.49 [CI = 1.12– 1.98]).11
Thus far, the reported data are from clinical trials, which 
included a small number of events, and real- world and phar-
macovigilance data are not yet available. In this manuscript, 
we used two real- world data sources– FDA’s Adverse Event 
Reporting System (FAERS) and Truven Health Analytics/
IBM MarketScan Commercial Claims database to study the 
reporting of CVAEs for patients on BRAF inhibitors alone 
versus combination BRAF/MEK inhibitors, along with asso-
ciated risk factors and outcomes.
2 |  METHODS
2.1 | Data source
A cross- sectional analysis was done using the FAERS dataset 
due to its design. The FAERS is a pharmacovigilance sys-
tem maintained by the FDA that includes AE reports that are 
voluntarily submitted. This registry provides data for post- 
marketing safety surveillance and adheres to the interna-
tional safety reporting guidance issued by the International 
Conference on Harmonization (ICH E2B), where all adverse 
events are coded using terms in the Medical Dictionary for 
Regulatory Activities.12 We searched the FAERS registry 
from January 1, 2011, to September 30, 2019, for adverse 
events reported for BRAF inhibitors (vemurafenib, dab-
rafenib, encorafenib) or a combination of BRAF/MEK inhib-
itors (vemurafenib (BRAF)/cobimetinib (MEK), dabrafenib 
(BRAF)/trametinib (MEK), and encorafenib (BRAF)/bini-
metinib (MEK)) among patients ≥18 years of age, excluding 
reports that did not specify patient age, gender, and type of 
cancer.
hypertension (ROR  =  1.75 (CI  =  1.12– 2.89); p  =  0.02) and VTE (ROR  =  1.80 
(CI = 1.12– 2.89); p = 0.02). Marketscan had 657 patients with median age of 53 years 
(IQR 46– 60), 39.3% female, and 88.7% with melanoma. There were 26.2% CVAEs 
(CI: 14.8%– 36%) within 6 months of medication start in those receiving combina-
tion therapy versus 16.7% CVAEs (CI: 13.1%– 20.2%) among those receiving mono-
therapy. Combination therapy was associated with CVAEs compared to monotherapy 
(adjusted HR: 1.56 (CI: 1.01– 2.42); p = 0.045).
Conclusions and Relevance: In two independent real- world cohorts, combination 
BRAF/MEK inhibitors were associated with increased CVAEs compared to mono-
therapy, especially HF, and hypertension.
K E Y W O R D S
BRAF inhibitors, BRAF/MEK inhibitors, cardiotoxicity, cardiovascular adverse events, FAERS, 
Marketscan, pharmacoepidemiology
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Longitudinal analysis was done using Truven Health 
Analytics/IBM MarketScan Commercial Claims, and 
Encounters Database was available from January 1, 2011, 
to December 30, 2018. The Truven Health Analytics/IBM 
MarketScan Database consists of de- identified outpatient, inpa-
tient, and pharmaceutical claims using over 50 million privately 
insured patients each year obtained from 150 large employer- 
sponsored health insurance plans in all 50 states. We queried 
the entire dataset for the prescription of drugs listed above using 
the International Classifications of Disease version 9 and 10 
(ICD- 9 CM and ICD- 10 CM) codes and created a subset that 
included patients with at least one prescription of BRAF mono-
therapy or combination BRAF/MEK. The enrolment of at least 
90 days before drug initiation was required to ensure adequate 
risk factor analysis for adjudicated events.
This study is compliant with the Declaration of Helsinki, 
and given the retrospective nature of the data- informed con-
sent was not required. The data that support the findings from 
the FAERS part of this study are openly available in raw for-
mat at https://bit.ly/37cHoXC. The data that support the find-
ings of the Truven Health Analytics/IBM MarketScan part 
of the study is available from IBM. Restrictions apply to the 
availability of these data, which were used under license for 
this study. Thus, this data cannot be shared directly by the 
authors.
2.2 | Outcomes
The primary outcome of this study is the proportion of CVAEs 
by dataset, classified into hypertension, atrial fibrillation, HF 
and reduced LVEF, QT prolongation/ventricular arrhythmia, 
pulmonary embolism/deep vein thrombosis/venous thrombo-
embolism, myocardial infarction (MI), and stroke. All- cause 
mortality stratified by CVAE event is a secondary outcome 
in the Truven Health Analytics/IBM MarketScan dataset. 
Mortality, hospitalization, and major adverse cardiovascular 
events (MACE) among adverse events were secondary out-
comes in the FAERS registry. MACE was defined as any 
CVAEs or mortality.
In the FAERS dataset, reported adverse events are a com-
bination of symptoms and diagnoses that are classified into 
25 subcategories according to ICH E2B. Specific cardiovas-
cular disorders were identified through keywords detailed in 
Table S1.
In the Truven Health Analytics/IBM MarketScan data-
set, the outcomes were identified in the inpatient, outpatient, 
and provider claims files using ICD- 9 CM and ICD- 10 CM 
codes. The National Cancer Institute (NCI) Macro,13 de-
signed to identify comorbidities, was repurposed to identify 
primary outcomes and other diagnoses.14 The first date of 
diagnosis of the outcomes was tabulated and adjudicated as 
an event if the patient did not have the outcome before the 
first prescription of the drug. QT prolongation/ventricular ar-
rhythmia could not be identified with certainty in the Truven 
Health Analytics/IBM MarketScan dataset and was only 
studied using FAERS. All the ICD- 9 CM and ICD- 10 CM of 
the outcomes are listed in Table S1.
2.3 | Covariates
2.3.1 | FAERS
The FAERS event report form for each patient consists of 
a case identification number, suspected medication, reason 
for use, adverse reactions, nature of the event (i.e., serious 
vs. non- serious), outcomes (hospitalization, death, and other 
outcomes), weight, event date, the pharmaceutical company, 
reporter (e.g., health care professional, consumer, a pharma-
ceutical company or unknown), concomitant medications, 
and country of event.15 Age was tiered into 18– 39, 40– 59, 
60– 79, and ≥80 years.
2.3.2 | Truven Health Analytics/
IBM MarketScan
Claims within 5 years prior to the use of the drug therapy 
were used to generate the NCI comorbidity index. Death was 
available as an outcome before January 1, 2016. However, 
for performing competing risk analysis, death had to be de-
fined using other variables, which are indicative of death 
(Supplemental methods).
2.4 | Statistical analysis
2.4.1 | FAERS and Truven Health Analytics/
IBM MarketScan
All continuous variables were assessed with the Shapiro- Wilk 
test and visual histogram check for normality. Descriptive 
statistics using the chi- squared test for categorical variables 
and Wilcoxon test/Student's t- test for continuous variables 
were used to differentiate the demographic and clinical char-
acteristics of those who received combination therapy versus 
monotherapy.
2.4.2 | FAERS
Multivariable polytomous logistic regression controlling 
for age, sex, cancer type, and data reporting source was per-
formed to present the reported odds- ratio of primary CVAE 
outcomes in combination therapy versus monotherapy.16
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2.4.3 | Truven Health Analytics/
IBM MarketScan
Univariate comparisons between BRAF monotherapy ver-
sus combination therapy were performed using the Kaplan– 
Meier method, and comparisons were made using the 
log- rank (Mantel– Cox) test. A multivariable Cox regression 
model was used to evaluate the risk of CVAEs in combina-
tion versus monotherapy in our entire cohort. A multivari-
able adjustment was made for age (groups ≤35, 35 to 50, 
>50 to 64, and ≥65 years of age), year of cancer diagnosis 
(2011– 2014, and 2015– 2018), NCI comorbidity score (0 
and >0), prior hypertension, insurance (Preferred Provider 
Organization [PPO], Health Maintenance Organization 
[HMO], and other), and geographical region (northeast, 
north- central, south, west, and unknown). Given the high 
mortality rates observed with cancers treated with MEK or 
BRAF inhibitors, we also performed a sensitivity analysis 
using multivariable Fine and Gray regression to evaluate 
for each of the CVAEs, using death as a competing event, 
and comparisons were made using the Gray K- sample 
test. Cause- specific multivariable hazards ratio (HR) was 
presented.
The alpha for the analysis was set at 0.05. The classifica-
tion of adverse events and hierarchical clustering analysis in 
FAERS was performed in Python 3.8.1, and the remaining 
statistics were performed using SAS 9.4.
3 |  RESULTS
The overall study design is presented as a consort diagram 
in Figure 1.
3.1 | FAERS (cross- sectional analysis)
3.1.1 | Demographics
Baseline characteristics of the FAERS population are pre-
sented in Table  1. Overall, 7712 adverse events were re-
ported between 2011 and 2019, with the highest number 
of adverse events reported in 2016 (16.9% of all reports). 
Among reported adverse events, 4659 (60.4%) were noted in 
those receiving combination BRAF/MEK therapy compared 
to 3053 (39.6%) receiving monotherapy. The median age of 
those reporting adverse events was 60 years (IQR =49– 69), 
and 44.9% were females. The most common source of the 
report were healthcare professionals (84.1%), followed by 
drug manufacturers (14.7%). Hospitalization was required 
for 46.2% of these adverse events, and 1427 (18.5%) died of 
adverse events.
Among those who were on BRAF inhibitor monother-
apy, the related adverse events were reported in vemurafenib 
(90.0%), dabrafenib (9.9%), and encorafenib (0.1%). Among 
those experiencing adverse events with combination ther-
apy, dabrafenib (BRAF)/trametinib (MEK),  vemurafenib 
(BRAF)/cobimetinib (MEK), and encorafenib (BRAF)/
binimetinib (MEK) were the responsible drug combinations 
in 73.8%, 24.9%, and 1.3%, respectively.
In a multivariable logistic regression model adjusted for age, 
gender, cancer type, and reporting source, all adverse events 
resulting in hospitalization (ROR  =  1.64 (CI  =  1.49– 1.81); 
p  <  0.0001) were significantly associated with combination 
therapy in comparison to monotherapy. However, there was no 
difference in all adverse events resulting in mortality (reporting 
odds ratio [ROR] = 0.90 (CI = 0.80– 1.01); p = 0.08) when 
comparing combination therapy to monotherapy.
F I G U R E  1  Consort diagram
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3.1.2 | Cardiovascular adverse events
All cardiovascular adverse events represented 567 (7.4%) of 
all reported adverse events. The median age was 67  years 
(IQR  =  57– 74), and 45.8% were females. Hospitalization 
was required in 64.8% of cases, and 18.4% died. The 
most common adverse event was HF 154 (27.2%). In a 
multivariable logistic regression model adjusted for age, gen-
der, cancer type, and reporting source, HF (reporting odds 
ratio [ROR] = 1.62 (CI =1.14– 2.30); p = 0.007), arterial hy-
pertension (ROR  =  1.75 (CI  =  1.12– 2.89); p  =  0.02) and 
venous thromboembolism (ROR  =1.80 (CI  =  1.12– 2.89); 
p  =  0.02) were significantly associated with combination 





Female, N (%) 2118 (45.5) 1367 (44.8) 0.56
Age, N (%) 0.0002
18– 39 years 500 (10.7) 291 (9.5)
40– 59 years 1738 (37.3) 1154 (37.8)
60– 79 years 2177 (46.7) 1378 (45.1)
≥80 years 244 (5.3) 230 (7.5)
Type of cancera — 
Melanoma, N (%) 4406 (94.6) 2947 (96.5) <0.0001
Non- small cell lung cancer, 
N (%)
321 (6.9) 106 (3.5) <0.0001
Colon cancer, N (%) 34 (0.7) 38 (1.3) 0.02
Year of reporting, N (%) <0.0001
2011– 2014 674 (14.5) 1862 (61.0)
2015– 2019 3985 (85.5) 1191 (39.0)
Reporting source, N (%) <0.0001
Consumer 0 (0) 15 (0.5)
Pharmaceutical company 4004 (85.9) 2460 (80.6)
Healthcare professional 642 (13.8) 511 (16.8)
Other 13 (0.3) 67 (2.2)
Reaction type, N (%) <0.0001
Serious 4271 (91.7) 2640 (86.5)
Non- serious 388 (8.3) 413 (13.5)
Hospitalized, N (%) 2378 (51.0) 1180 (38.7) <0.0001
Died, N (%) 627 (20.0) 853 (18.3) 0.053
Specific cardiac events, N 
(%)b 
380 (8.2) 187 (6.1) 0.0008
Pulmonary embolismc 56 (14.6) 19 (9.9) 0.03
Venous thromboembolismc 65 (17.2) 23 (12.5) 0.03
Arterial hypertensionc 62 (16.4) 23 (12.5) 0.047
Heart failurec 110 (29.0) 44 (23.4) 0.03
Deep vein thrombosisc 14 (3.6) 6 (3.1) 0.19
Atrial fibrillationc 62 (16.2) 33 (17.7) 0.08
Myocardial infarctionc 44 (11.5) 27 (14.6) 0.01
QT prolongationc 65 (17.2) 45 (24.0) 0.06
Strokec 9 (2.3) 8 (4.2) 0.09
aFew events have more than 1 reported cancer.
bHypertension, atrial fibrillation, HF and reduced LVEF, QT prolongation/ventricular arrhythmia, pulmonary 
embolism/deep vein thrombosis/venous thromboembolism, myocardial infarction, and stroke.
cThe proportions reflect that among CVAEs.
T A B L E  1  Characteristics of all 
adverse events with BRAF/MEK inhibitor 
combination therapy versus monotherapy 
with BRAF inhibitors in FDA Adverse 
Event Dataset
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multivariable odds ratio comparing the likelihood of occur-
rence of various CVAEs with the combination versus mono-
therapy is presented in Figure 2.
In a multivariable logistic regression model adjusted 
for age, gender, cancer type, and reporting source, there 
was no difference in CVAEs resulting in hospitalization 
(ROR = 1.15 (CI = 0.79– 1.67); p = 0.46) or CVAEs resulting 
in mortality (reporting odds ratio [ROR] = 0.89 (CI =0.56– 
1.39); p  =  0.60) when comparing combination therapy to 
monotherapy.
3.2 | Truven Health Analytics/IBM 
MarketScan (longitudinal analysis)
3.2.1 | Demographics
Baseline characteristics of those receiving BRAF mono-
therapy compared to BRAF/MEK combination therapy in 
the Truven Health Analytics/IBM MarketScan database are 
presented in Table 2. Overall, 657 patients with cancer repre-
senting 707.4 person- years of follow- up met the study crite-
ria. The Median follow- up time was 207 days (IQR 85– 476). 
BRAF/MEK combination versus BRAF monotherapy was 
utilized in 112 (17.1%) versus 545 (82.9%) patients. The me-
dian age was 53 years (IQR 46– 60), and 39.3% were females. 
The most common malignancy was melanoma (88.7%), and 
most patients had PPO insurance (63.6%). The overall use 
of anthracycline and radiotherapy in this cohort before the 
use of MEK or BRAF/MEK inhibitor was 0.5% and 7.9%, 
respectively.
3.2.2 | Cardiovascular events
Overall, 185 (28.2%) patients had incident CVAEs during 
the follow- up period. There were 26.2% CVAEs (CI: 14.8%– 
36%) within 6 months of medication start in those receiving 
combination therapy versus 16.7% CVAEs (CI: 13.1%– 
20.2%) among those receiving monotherapy (Table 3). In a 
Cox regression model, the risk of all CVAEs was not sta-
tistically different among combination versus monotherapy 
(HR: 1.45 (CI: 0.99– 2.13). However, when accounting for 
competing risk of death and adjusting for NCI comorbidity 
index, year of diagnosis, insurance status, and radiation ther-
apy, combination therapy was associated with a higher risk 
of CVAEs compared to monotherapy (Adjusted HR: 1.56 
(CI: 1.01– 2.42); Gray K- Sample p- value: 0.045, Figure 3A). 
During follow- up, 13 patients in the BRAF monotherapy arm 
had HF (6- month rate of 1.9% (CI: 1.0– 3.9%)) compared to 
5 patients in the BRAF/MEK combination arm (6- month rate 
of 6.9% (CI: 2.8– 16.7%); Figure 3B). HTN event was noted 
in 73 in the BRAF monotherapy arm versus 19 patients in 
the BRAF/MEK combination arm (6- month rate 7.1% (CI: 
5.1%– 10.0%) versus 11.3% (CI: 5.7– 22.7%); Figure 3C).
Cox regression HR, cause- specific HR accounting for 
competing risk, and 6- month rate of an event of combina-
tion therapy versus monotherapy for individual events of HF, 
ischemic stroke, PE, DVT, VTE, new or worsening arterial 
hypertension, AF, and all CVAEs is presented in Table 2. The 
competing risk model plots for combination versus mono-
therapy are presented for stroke, VTE, and AF is shown in 
Figure S1A– C. None of the individual events achieved statis-
tical significance, but HF (HR: 2.66, Gray K- Sample p- value: 
F I G U R E  2  Cardiovascular Events and adjusted reporting odds ratio for MEK and BRAF combination therapy events versus monotherapy 
with BRAF inhibitors in the FDA Adverse Event Dataset. It was adjusted for age, gender, cancer type, and reporting source. MACE (major adverse 
cardiovascular event) is defined as any cardiac event in the list reported here or mortality
3868 |   GUHA et Al.
0.052) and new or worsening arterial hypertension (HR: 1.66, 
Gray K- Sample p- value: 0.06) tended toward significance.
There was no difference in all- cause mortality among 
those who do not have any CVAEs versus those who have a 
CVAE, regardless of combination or monotherapy (HR: 1.11, 
Log- Rank p- value: 0.53; Figure 4).
4 |  DISCUSSION
In this study spanning 8 years using a large national pharma-
covigilance database and a longitudinal cohort of privately 
insured patients, BRAF/MEK combination therapy was 
adversely associated with cardiovascular events compared 
to BRAF monotherapy. In a cross- sectional pharmacovigi-
lance analysis, HF, VTE, and arterial hypertension were sig-
nificantly associated with combination therapy. There was 
no difference in hospitalization or mortality reported with 
CVAEs when stratified by type of therapy. On longitudinal 
follow- up, overall cardiovascular events were significantly 
associated with combination therapy versus monotherapy 
when accounting for competing risk of death. Collectively, 
both cohorts demonstrated a higher tendency for heart failure 
and new or worsening hypertension as events, particularly 
in those receiving combination therapy compared to mono-
therapy in a “real- world” setup, thus justifying a reason to 
follow them closely by cardio- oncology during their therapy.
HF was noted to be significantly associated with com-
bination therapy in the FAERS registry but not in the 
Truven Health Analytics/IBM MarketScan registry. In the 
meta- analysis by Mincu et al., the relative risk of LVEF 
decline was 3.72.11 It should be recognized in our study, 
we specifically evaluated for symptomatic heart failure, 





Female, N (%) 48 (42.9) 210 (38.5) 0.39
Age, N (%) 0.69
<35 years 8 (7.1) 38 (7.0)
35– 50 years 42 (37.5) 182 (33.4)
>50– 65 62 (55.4) 325 (59.6)
Type of cancer, N (%) — 
Melanoma 107 (95.5) 476 (87.3)
Non- small cell lung cancer 8 (1.5) 0
Colon cancer 23 (4.2) 3 (2.7)
Others 38 (7.0) 2 (1.8)
Year of diagnosis, N (%) <0.0001
2011– 2014 11 (9.8) 476 (87.3)
2015– 2018 101 (90.2) 69 (12.7)
Median follow up, days 
(median, IQR)
130 (51– 363) 234 (95– 506) 0.0003
NCI comorbidities, N (%) <0.0001
0 72 (64.3) 444 (81.5)
≥1 40 (35.7) 101 (18.5)
Pre drug start comorbidities, 
N (%)
Hypertension 28 (17.4) 95 (25.0) 0.06
Diabetes 13 (11.6) 40 (7.3) 0.13
Coronary artery disease 4 (3.6) 6 (1.1) 0.06
Congestive heart failure 3 (2.7) 8 (1.5) 0.18
Atrial fibrillation 2 (1.8) 11 (2.0) 0.29
Stroke 6 (5.4) 35 (6.4) 0.67
Venous thromboembolism 9 (8.0) 16 (2.9) 0.01
Anthracycline use, N (%) 0 3 (0.6) — 
Radiation use, N (%) 29 (4.2) 23 (25.9) <0.0001
T A B L E  2  Characteristics of BRAF/
MEK inhibitor combination therapy versus 
monotherapy with BRAF inhibitors in 
Truven Health Analytics/IBM MarketScan 
Dataset
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and not associated with clinical heart failure. As such, our 
lower OR of 1.62 for HF with dual therapy is expected 
and consistent with prior findings. Most HF events were 
noted in the first 6  months in the combination arm. In 
the 5- year follow- up analysis of the COmbined LGX818 
(encorafenib) used with MEK162 (binimetinib) in BRAF 
mutant Unresectable Skin cancer (COLUMBUS) trial,17 
LVD events were noted mostly in the first 6 months (5.1%) 
compared to 6– 12 month (3.4%), 12– 18 month (3.4%) and 
18– 24 month period (1.7%).
Similar to HF, HTN was also significantly higher in the 
combination therapy arm in the FAERS registry but not in 
the Truven Health Analytics/IBM MarketScan registry. 
Apart from being identical to the meta- analysis,11 this data 
relates well with the data presented in the 5- year analysis of 
the COMBI- V and COMBI- D trial, which showed that 29% 
of patients had a hypertension event.18 In another 3- year 
safety study of the COMBI- V trial, HTN was noted in 24% 
of those with combination therapy compared to 16% in those 
receiving monotherapies.6 In another study comparing ve-
murafenib versus vemurafenib and cobimetinib combination 
therapy in those with metastatic melanoma (coBRIM), sig-
nificantly higher HTN was noted in the combination therapy 
arm (15.4%) compared to the control arm (8.1%).19 These 
data suggest that attention should be paid to blood pressure in 
patients initiated on monotherapy or combination therapy as 
hypertension has been implicated in the risk of stroke, heart 
failure, and coronary artery disease in patients with cancer.20
The knowledge of the significant cardiovascular toxicity 
profile of these combinatorial regimens highlighted in our 
study and others21 is vital to anticipate specific off- target 
CVAE and thus screen accordingly and take effective mea-
sures early in treatment, including cardiology referral for 
co- management to prevent cardiovascular toxicity and un-
necessary treatment disruption. Similar to other cytotoxic 
and targeted therapies, there may be a role for early surveil-
lance with imaging, or biomarkers may be necessary early 
after combination therapy initiation. Studies have shown that 
12% of patients with a normal LVEF at the completion of 
anthracycline- based chemotherapy with ultimately develop 
dysfunction in subsequent years.22 As such, troponin mon-
itoring with each cycle therapy is recommended to identify 
those at risk for cardiotoxicity and allow for intervention be-
fore permanent damage has occurred.23,24 Similarly, regular 
monitoring for LVEF and global longitudinal strain changes 
may help minimize trastuzumab- related cardiac dysfunc-
tion, which can approach 25% when used sequentially with 
anthracyclines.23,25,26
The pathophysiology of BRAF and MEK- associated car-
diotoxicity remains uncertain though various hypotheses 
have been suggested based on data from basic and trans-
lational studies.27– 29 There is evidence to suggest that the 
T A B L E  3  Hazards Ratio for events in BRAF/MEK inhibitor combination therapy versus monotherapy with BRAF inhibitors in Truven Health 
Analytics/IBM MarketScan dataset
Event
Events at 6 months in combination 






Hazard Ratioc p- valued 
Heart failure 5 (4.8%) versus 13 (1.4%) 2.52 
(0.89– 7.11)
2.66 (0.96– 7.38) — 0.07/0.052
Stroke 6 (9.2%) versus 28 (6.2%) 1.37 
(0.75– 2.51)
1.50 (0.85– 2.67) — 0.30/0.17
Pulmonary embolism 1 (1.8%) versus 9 (2.3%) 1.08 
(0.32– 3.68)
1.13 (0.33– 3.88) — 0.90/0.83
Deep vein thrombosis 1 (2.2%) versus 6 (2.3%) 1.11 
(0.33– 3.77)
1.25 (0.37– 4.25) — 0.87/0.72
Venous 
thromboembolism
1 (2.2%) versus 9 (2.3%) 0.94 
(0.33– 2.67)
1.13 (0.33– 3.86) — 0.90/0.83
New arterial 
hypertension
8 (11.1%) versus 32 (6.3%) 1.56 
(0.92– 2.65)
1.66 (0.99– 2.79) — 0.10/0.06
Atrial fibrillation 2 (2.9%) versus 8 (3.3%) 0.80 
(0.18– 3.49)
0.86 (0.20– 3.77) — 0.77/0.87
All cardiovascular 
eventse 
19 (26.2%) versus 73 (16.7%) 1.45 
(0.99– 2.13)
1.55 (1.08– 2.23) 1.56 (1.01– 2.42)f 0.06/0.045
aCompeting risk of mortality.
bCalculated using the lifetable method of events/number at risk.
cOnly if the univariable model significant.
dLog- rank test/Gray K- Sample test of univariable Cox model unless a multivariable model is used. In that case, a multivariable p- value is presented.
eComposite of heart failure, stroke, venous thromboembolism, hypertension, and atrial fibrillation.
fAdjusted for the year of diagnosis, NCI comorbidity index, type of insurance since those were significantly different in the cohort.
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MAPK pathway may be cardioprotective; BRAF and MEK 
inhibitors inhibit this pathway and can lead to hypertrophy, 
apoptosis, cardiac remodeling, and declines in LVEF as well 
as arterial hypertension via effects on nitric oxide production. 
Similarly, hypertension may result from BRAF and MEK ef-
fect on the renin- angiotensin system.
Multiple limitations should be acknowledged. First, this 
is a retrospective pharmacovigilance study from a public 
registry and a retrospective cohort. The FAERS data is vol-
untarily reported by both patients and the medical commu-
nity and requires no confirmation or scientific rigor, which 
leads to potential reporting and attribution biases. Truven 
Health Analytics/IBM MarketScan database does not con-
tain a random sample of patient claims data but rather a co-
hort primarily drawn from large employers. Patients who are 
self- insured and those insured through small and medium 
employers are underrepresented in the dataset. Similarly, 
patients covered only by public insurance (e.g., Medicaid, 
traditional Medicare, and Medicare Advantage) could not 
be included; however, using two datasets helped overcome 
that limitation somehow. FAERS data lack temporality due 
to its cross- sectional nature, but we addressed that issue 
with the Truven Health Analytics/IBM MarketScan data-
set. Even though FAERS lacked prior cardiovascular condi-
tions, vital signs, and laboratory values including troponin 
or brain natriuretic peptide, electrocardiogram, echocar-
diogram or advanced cardiovascular, or oncologic diag-
nostic workup, Truven Health Analytics/IBM MarketScan 
was able to provide a significant number of these covari-
ates, thus helping study profile of these patients. However, 
the Truven Health Analytics/IBM MarketScan dataset re-
lies heavily on coders’ accuracy and is not comprehensive 
of all provider and patient characteristics. Truven Health 
Analytics/IBM MarketScan database did not have a suf-
ficient number of patients indicating a lack of power to 
achieve statistical significance. Stated differently, some of 
F I G U R E  3  Competing risk analysis of (A) cardiovascular events, (B) heart failure, and (C) new or worsening hypertension in those receiving 
MEK and BRAF combination therapy versus monotherapy with BRAF inhibitors from Truven Health Analytics/IBM MarketScan dataset
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the CVAEs had very low incidence, thus risking a signifi-
cant likelihood of type 2 error. Additionally, BRAF/MEK 
combination therapy has a much longer progression- free 
survival than single- agent BRAF inhibitor, which leads to 
a more prolonged exposure that could partly account for 
the added toxicity. We could not account for the length of 
exposure in either data sets in a reliable manner. Lastly, 
the FAERS registry remains prone to issues related to all 
passive surveillance reporting systems, such as under- , 
over- , and duplicate reporting (despite efforts to exclude 
duplicate reports), varying report quality, and absence of 
denominator data.30– 32 Accordingly, it is possible more car-
diac adverse events may have gone uncaptured.
5 |  CONCLUSION
In these pharmacovigilance analyses spanning eight years 
and two large datasets, combination BRAF/MEK inhibitors 
were associated with increased CVAEs compared to BRAF 
monotherapy. Heart failure and hypertension are the most 
common events in this “real world” analysis, thus justifying 





FAERS data are publicly available and does not require ap-
proval by the Institutional Review Board. Truven Health 
Analytics/IBM MarketScan dataset is de- identified, an 
exemption was obtained from the University Hospitals’ 
Institutional Review Board.
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